US 11,938,124 B2
Combination therapy for treatment of cancer
Arnold Levine, Doylestown, PA (US); and Melissa Dumble, Watchung, NJ (US)
Assigned to PMV Pharmaceuticals, Inc., Princeton, NJ (US)
Filed by PMV Pharmaceuticals, Inc., Cranbury, NJ (US)
Filed on Jun. 15, 2021, as Appl. No. 17/348,490.
Claims priority of provisional application 63/162,184, filed on Mar. 17, 2021.
Claims priority of provisional application 63/043,342, filed on Jun. 24, 2020.
Prior Publication US 2023/0033324 A1, Feb. 2, 2023
Int. Cl. A61K 31/454 (2006.01); A61K 31/404 (2006.01); A61K 31/4045 (2006.01); A61K 31/438 (2006.01); A61K 31/4439 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/538 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/454 (2013.01) [A61K 31/404 (2013.01); A61K 31/4045 (2013.01); A61K 31/438 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/538 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] 28 Claims
OG exemplary drawing
 
1. A method of treating a cancer in a subject in need thereof, the method comprising:
(i) administering to the subject a therapeutically-effective amount of a compound of the formula:

OG Complex Work Unit Chemistry
wherein:
R3 is H;
R4 is C4-C6-heterocyclyl substituted with at least halo-;
R16 is hydrogen; and
R17 is aryl that is substituted or unsubstituted,
or a pharmaceutically-acceptable salt thereof; and
(ii) administering to the subject a therapeutically-effective amount of an immune checkpoint inhibitor.